Anthony P. Adamis's Insider Trades & SAST Disclosures
Anthony P. Adamis's most recent trade in Kalaris Therapeutics Inc. was a trade of 18,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Anthony P. Adamis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics Inc. | Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | P. Adamis Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges